Novo Nordisk
NVO
1,049 hedge funds and large institutions have $19.3B invested in Novo Nordisk in 2022 Q4 according to their latest regulatory filings, with 206 funds opening new positions, 296 increasing their positions, 353 reducing their positions, and 49 closing their positions.
320% more first-time investments, than exits
New positions opened: 206 | Existing positions closed: 49
77% more call options, than puts
Call options by funds: $252M | Put options by funds: $142M
64% more funds holding in top 10
Funds holding in top 10: 28 → 46 (+18)
40% more capital invested
Capital invested by funds: $13.8B → $19.3B (+$5.48B)
16% more funds holding
Funds holding: 907 → 1,049 (+142)
0.51% more ownership
Funds ownership: 15.94% → 16.45% (+0.51%)
16% less repeat investments, than reductions
Existing positions increased: 296 | Existing positions reduced: 353
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$412M |
| 2 |
Morgan Stanley
New York
|
+$173M |
| 3 |
Millennium Management
New York
|
+$131M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$81M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$78.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$317M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$71.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$65.5M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$46.5M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$36M |
NVO Hedge Fund Activity: Q4 2022 in Review
1,049 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2022, worth a combined $19.3B — up 40% from $13.8B a quarter earlier.
Buyers outnumbered sellers: 206 funds opened new NVO positions and 49 closed out — a net gain of 157 holders — while 296 added to existing stakes and 353 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $412M. The largest seller was Renaissance Technologies, cutting an estimated $317M.
- 1,049 institutional investors held Novo Nordisk (NVO) as of Q4 2022, up from 907 in Q3 2022.
- Funds reported $19.3B of Novo Nordisk stock for Q4 2022, up 40% quarter-over-quarter.
- 206 funds opened new Novo Nordisk positions in Q4 2022 and 49 closed out, a net change of +157 holders.
- The largest Novo Nordisk buyer in Q4 2022 was Fidelity Investments, an estimated $412M added.
- The largest Novo Nordisk seller in Q4 2022 was Renaissance Technologies, an estimated $317M sold.
Based on aggregated 13F filings for Q4 2022.